If you liked this article you might like

FTC Details Concerns on Generic Drug Company Mergers
Mylan Is Done Leaning on EpiPen Sales and That Could be a Big Problem
Teva Stock Gains, Leerink: Despite Patent Loss, No Generic Competition Until 2018
Why EpiPen, Why Now? Analysts Explain the Timing of Mylan's Trouble